Purchase Order 36C26126P0483

Edwards Lifesciences LLC received a firm fixed-price purchase order valued at $68,000 from Veterans Integrated Service Network 21 (VISN 21) for two transcatheter aortic valve replacement (TAVR) surgical implants. The contract, awarded on February 17, 2026, with completion targeted for the same date, will support cardiac surgical services at the VA Palo Alto Health Care System in Palo Alto, California. This procurement carries no set-aside designation and represents a specialized medical device acquisition for which Edwards Lifesciences maintains exclusive manufacturing capability. The award is positioned as a child contract under the company's broader five-year, $6.5 million Indefinite Delivery Contract with VISN 21, which provides a consignment model framework enabling the VA facility to maintain inventory of Edwards Lifesciences' advanced cardiovascular devices and procure them on an as-needed basis for surgical procedures.

Edwards Lifesciences LLC, a self-certified small disadvantaged business and subsidiary of Edwards Lifesciences Corporation, is a global leader in transcatheter heart valve technology and structural heart disease innovations. The company has established itself as a critical supplier to the Department of Veterans Affairs, with over 200 prime federal contract awards since 2025 distributed across multiple Veterans Integrated Service Networks. This specific TAVR procurement aligns with the VA's broader cardiac care mission and supports veteran patient outcomes through the provision of state-of-the-art surgical implant technology essential to advanced cardiac surgical programs.